Background--The aim of this study was to elucidate aspects of diabetes mellitus-induced suppression of aneurysm. We hypothesized that high glucose suppresses aneurysm by inhibiting macrophage activation via activation of Nr1h2 (also known as liver X receptor b), recently characterized as a glucose-sensing nuclear receptor.
A ortic aneurysm is a significant medical condition with high prevalence in men aged >65 years and significant mortality. 1 Previous studies suggested that the pathogenesis of aneurysm is closely associated with chronic inflammation of the aortic wall, the local activation of proteinases, and the degradation of matrix proteins by matrix metalloproteinases produced from activated macrophages. 1, 2 Currently, surgical
intervention with either open repair or endovascular stent graft placement is the only proven treatment for aneurysm, but it has significant associated morbidity and mortality, indicating the urgent need for alternative therapeutic strategies. Diabetes mellitus (DM) is also a significant medical condition. A major feature of DM-induced vascular pathology is severe calcification of the medial layer of the artery that eventually causes stenosis or occlusion and ischemic changes to the target organs in conditions such as coronary artery disease, peripheral artery disease, and ischemic stroke. 3, 4 It is interesting that recent large epidemiological studies have shown that DM is an independent negative risk factor for aneurysm, although it shares most of the same common risk factors as stenotic arterial disease, including male sex, aging, hypertension, dyslipidemia, and smoking. 5, 6 Nr1h1 and Nr1h2 (also known as liver X receptor [LXR] a and b, respectively) were recently characterized as glucosesensing nuclear receptors, although they have been identified for some time. 7 There has also been great interest in these receptors as novel therapeutic targets for inflammatory diseases because they inhibit inflammatory gene expression downstream of signaling mediated by Toll-like receptor 4, interleukin 1b, and tumor necrosis factor a (TNF-a). 8, 9 Robertson Remen et al 10 demonstrated the effect of the Nr1h (LXR) agonist GW3965 in lipopolysaccharide-induced differentiation of bone marrow-derived macrophages into osteoclasts via an Nr1h2-dependent (but not an Nr1h1-dependent) mechanism. Although there have been several reports regarding the underlying mechanisms of DM suppression of aneurysm, the effects of DM on macrophages and aneurysmal degeneration are still controversial. Macrophage subpopulations identified by CD68, a macrophage marker, were reported to be significantly higher in diabetic versus nondiabetic patients.
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In contrast, Miyama et al 12 showed that hyperglycemia attenuates macrophage infiltration in a mouse model of aneurysm induced by porcine pancreatic elastase. In this study, we focused on how high glucose affects macrophage activation and aneurysm formation through Nr1h2.
Materials and Methods

Materials
TNF-a and GW3965 were purchased from Peprotech and Santa Cruz Biotechnology. Streptozotocin (STZ) was purchased from Sigma-Aldrich. All chemicals used in this study were of the highest purity available.
Cell Culture
Murine monocytic RAW264.7 cells were purchased from American Type Culture Collection (Manassas, VA) and maintained in Dulbecco's modified Eagle's medium (Mediatech) containing 10% FBS (Mediatech), 100 IU/mL penicillin, and 100 lg/mL streptomycin (Mediatech). For macrophage activation, 5910 5 cells were plated per well in a 6-well plate and maintained in minimal essential medium a (Mediatech) supplemented with 10% charcoal-stripped FBS with antibiotics.
Cell Viability
RAW264.7 cells were cultivated in 96-well plates (4000 cells per well) 1 day before treatment and were cultured with or without TNF-a plus calcium phosphate (CaPO 4 ), mannitol, and high glucose. The cells were combined with MTT solution (50 ng per well) and incubated for 4 hours. Acid isopropanol (0.04 N HCl in isopropanol) and 3% sodium lauryl sulfate were added to dissolve the reduced MTT crystals (formazan) present in the cells. After mixing, the absorbance was measured at 595 nm, with 655 nm as the reference, using a microplate reader.
Mouse Model of Aneurysm and Treatment
C57BL/6 or KK.Cg-Ay/J mice aged 10 weeks were obtained from the Jackson Laboratory (Bar Harbor, ME). The procedures for creating our modified CaCl 2 -induced mouse model of aneurysm were described previously. 13 We applied the procedure for the infrarenal aorta to the carotid artery in this study. Briefly, 0.5 mol/L CaCl 2 -soaked gauze was applied perivascularly for 10 minutes to the carotid artery. The gauze was replaced with PBS-soaked gauze for 5 minutes, and the incised area was sutured. The excess CaCl 2 is converted into CaPO 4 , and the crystals act as adjuvants. After 1 to 4 weeks, the mice were sacrificed, and the carotid arteries were collected after fixing by perfusion with 4% paraformaldehyde. 
Histological and Immunohistochemical Analysis
The murine carotid artery tissues obtained were fixed with 4% paraformaldehyde overnight. The samples were then embedded with OCT compound (Sakura Tissue Tek), frozen, and sectioned at a thickness of 6 lm per section. For histological analysis, the sections were stained with hematoxylin and eosin and observed by light microscopy (Olympus BH-2). Immunofluorescent staining was performed with rat anti-MOMA-2 (ab33451; Abcam) and donkey anti-rat Alexa 488 (Molecular Probes, Invitrogen). TO-PRO-3 stain (Molecular Probes, Invitrogen) was used to identify nuclei. Fluorescent staining was visualized, and digital images were taken on a Nikon A1R Laser Scanning Confocal imaging system with the appropriate argonbeam lasers.
Western Blotting
Protein extraction was performed at 0 to 4°C. Protein from cultured cells and isolated carotid arteries was extracted with a radioimmunoprecipitation assay buffer supplemented with a protease inhibitor cocktail (Cell Signaling Technology). Next, 20-µg samples were separated on 8%, 10%, or 12% polyacrylamide gels in Laemmli sample buffer and transferred electrophoretically onto polyvinylidene difluoride membranes. The membranes were blocked for 1 hour at room temperature in Tris-buffered saline containing 3% skim milk powder. The primary antibodies used for Western blotting included rabbit matrix metalloproteinase 9 (Mmp9; ab38898; Abcam), rabbit Nr1h2 (sc-1001; Santa Cruz Biotechnology), and mouse atubulin (sc-23948; Santa Cruz Biotechnology) antibodies. Primary antibodies were detected using a horseradish peroxidase-conjugated secondary antibody and visualized with the enhanced chemiluminescence kit (Thermo Scientific) or SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific).
Quantitative Polymerase Chain Reaction
Total RNA was extracted from RAW264. 
Gelatin Zymography
Gelatin zymography was performed using cell culture medium. The medium was separated with 12.5% SDS-PAGE with 1 mg/ mL gelatin incorporated into the gel mixture. Following electrophoresis at 4°C, the gel was washed in 2.5% Triton X-100 and incubated at 37°C for 16 hours in 50 mmol/L TrisHCl (pH 7.4) containing 10 mmol/L CaCl 2 and 0.05% Brij 35. The gels were then stained with 0.5% Coomassie blue in 30% isopropanol and 10% acetic acid for 1 hour and destained in 12.5% isopropanol and 10% acetic acid.
Statistical Analysis
Data are reported as meanAESD. Statistical analysis was performed with GraphPad Prism version 4.00 (GraphPad Software, Inc). Comparisons between groups at a single time point were performed using the Student t test. Multiple comparisons among treatments were performed by 1-way ANOVA, followed by the Tukey range test. For testing 2 samples from the same population ( Figures 1A, 1B , 2A, 2B, and 4E), the Wilcoxon rank sum test was used. P values <0.05 were accepted as statistically significant.
Results
Inhibition of CaPO 4 -Induced Aneurysm Formation by Hyperglycemia in a Mouse Model of STZInduced Type 1 Diabetes
To examine the effect of hyperglycemia on aneurysm formation in type 1 DM, mice were intraperitoneally injected with STZ or control vehicle. After 7 days, aneurysm was induced with CaPO 4 in a surgical procedure. First, we measured body weight and blood glucose levels and confirmed successful induction of DM in the STZ-induced mice ( Figure 1A and 1B) . We then induced aneurysm and compared the maximum diameter of the artery after 4 weeks. As shown in Figure 1C and 1D, injection of STZ significantly suppressed aneurysm formation, based on the fold increase of the maximum diameter of the artery at the time of the initial surgery and sacrifice (1.8AE0.2 versus 1.5AE0.2, P<0.05) ( Figure 1D ). These results suggest that CaPO 4 -induced aneurysm is suppressed by STZ-induced type 1 diabetes. Next, we examined whether macrophage accumulation was suppressed by STZ-induced DM in mice. Monocytes and macrophages, marked by MOMA-2, were localized mostly in the adventitia of mice in the CaPO 4 -induced aneurysmal model ( Figure 1E ). The number of monocytes and macrophages was markedly decreased in STZ-induced mice compared with controls.
Inhibition of CaPO 4 -Induced Aneurysm Formation by Hyperglycemia in a Mouse Model of KK-Ay Type 2 Diabetes
We examined the effect of type 2 DM on aneurysm formation by using KK-Ay mice, a model of type 2 DM. We first measured blood glucose levels and body weight. Although body weight showed no significant change in the 2 groups (Figure 2A ), blood glucose levels were consistently higher in the KK-Ay mice than in the control mice ( Figure 2B ). We then induced aneurysm with CaPO 4 in both KK-Ay and control wildtype mice. As shown in Figure 2C , aneurysm formation was suppressed in KK-Ay mice compared with control mice. The diameter of the artery (fold increase) in the KK-Ay mice was significantly lower than in the control mice (1.8AE0.2 versus 1.6AE0.1, P<0.05) ( Figure 2D ). The numbers of monocytes and macrophages were also decreased in KK-Ay mice compared with controls ( Figure 2E ). These results suggest that CaPO 4 -induced aneurysm formation was suppressed by the presence of type 2 diabetes in KK-Ay mice.
Inhibition of TNF-a and CaPO 4 -Induced Macrophage Activation by High-Glucose Treatment
TNF-a is known to be a key inflammatory mediator of aneurysm formation and macrophage activation. [14] [15] [16] We also reported that CaPO 4 crystals, a major component of arterial calcification, play an important role in aneurysm degeneration by inducing apoptosis of smooth muscle cells and macrophage infiltration. 13 Consequently, we established an in vitro aneurysm model by stimulating macrophages with TNF-a plus CaPO 4 crystals and used Mmp9 as a marker of classical macrophage activation. 17, 18 As shown in Figure 3A and 3B, treatment with TNF-a plus CaPO 4 significantly increased Mmp9 mRNA and secreted protein expression compared with TNF-a treatment alone (50.3AE3.5 versus 21.0AE1.0 and 7.5AE1.7 versus 2.7AE0.8, respectively, P<0.01), whereas CaPO 4 treatment alone did not affect Mmp9 expression.
Next, RAW264.7 macrophages were treated with hyperglycemic conditions using 15.5 mmol/L glucose (corresponding to 279.2 mg/dL) to mimic DM-induced hyperglycemia. As shown in Figure 3C and 3D, high-glucose treatment significantly attenuated the elevated Mmp9 mRNA and secreted protein expression induced by TNF-a plus CaPO 4 (17.9AE2.5 versus 50.5AE9.7 and 3.6AE0.5 versus 6.4AE0.3, respectively, P<0.01), whereas mannitol treatment, as a control for osmotic pressure, did not significantly affect Mmp9 mRNA or secreted protein expression. We performed the MTT assay and confirmed that high-glucose conditions did not affect cell viability ( Figure 3E ). To further examine the effect of high-glucose treatment on Mmp9 activity, gelatin zymography was performed. The medium from RAW264.7 cells treated with high-glucose conditions showed a decrease in gelatinolytic activity ( Figure 3F ), suggesting that high glucose suppresses Mmp9 activity induced by TNF-a plus CaPO 4 in macrophages.
Increased Nr1h2 Expression Levels by HighGlucose Treatment
To examine the mechanism by which high glucose suppresses macrophage activation, we next measured Nr1h2 mRNA expression levels. Treatment with TNF-a and CaPO 4 significantly decreased Nr1h2 mRNA expression compared with the control (0.2AE0.04 versus 1.0AE0.2, P<0.01) ( Figure 4A ), whereas high-glucose treatment significantly restored the decreased Nr1h2 mRNA expression (0.8AE0.4 versus 0.2AE0.04, P<0.05). Mannitol treatment showed no significant change in expression. As shown in Figure 4B , the same trend was observed in Nr1h2 protein expression. In the highglucose treatment group, Nr1h2 protein expression was significantly higher than in the normal glucose treatment group, according to densitometric analysis of Western blotting (1.1AE0.1 versus 0.9AE0.1, P<0.05). Next, to examine the effect of Nr1h2 activation on macrophages, RAW264.7 cells were treated with GW3965, an Nr1h (LXR) agonist. Although GW3965 treatment did not alter Mmp9 mRNA expression in the untreated cells, it dose-dependently suppressed Mmp9 expression induced by TNF-a plus CaPO 4 at 0.1 to 1 lmol/L ( Figure 4C ). The relative expression in the cells treated with 0.5 and 1 lmol/L GW3965 was significantly lower than in the control (51.7AE6.4 versus 66.7AE3.1 and 40.9AE3.0 versus 66.7AE3.1, respectively, P<0.05). We also examined the effects of Nr1h2 siRNA on Mmp9 expression induced by TNF-a plus CaPO 4 . As shown in Figure 4D , Nr1h2 siRNA knocked down Nr1h2 mRNA expression to 44% of control. In the cells treated with the siRNA control, high-glucose treatment significantly suppressed Mmp9 mRNA upregulation by TNF-a plus CaPO 4 (52.2AE10.7 versus 86.3AE2.2, P<0.05) ( Figure 4E ). In contrast, in the cells treated with Nr1h2 siRNA, the Mmp9 mRNA upregulation induced by TNF-a plus CaPO 4 was not suppressed by high-glucose treatment (99.3AE11.2 versus 91.3AE4.6). These results suggest the involvement of Nr1h2 in the mechanism by which high glucose suppresses Mmp9 expression in macrophages. 
Inhibition of Aneurysm Formation by GW3965
Finally, we examined the effects of GW3965 on CaPO 4 -induced aneurysm formation in mice. As shown in Figure 5A , administration of GW3965 (20 mg/kg), with the vehicle (PBS) solution as a control, was administered by intraperitoneal injection for 2 weeks, and this suppressed aneurysmal degeneration. When we calculated the fold increase based on the maximum diameter of the artery at the time of the initial surgery and sacrifice, the value for the GW3965-administration group was significantly lower than that for the control group (1.7AE0.2 versus 2.0AE0.2, P<0.05) ( Figure 5B ).
The number of monocytes and macrophages stained with MOMA-2 were also markedly decreased by GW3965 administration compared with the control ( Figure 5C ). Furthermore, GW3965 suppressed Mmp9 protein expression levels in the isolated carotids compared with the control group (0.4AE0.1 versus 1.0AE0.4, P<0.05) ( Figure 5D ). These results suggest that GW3965 suppresses aneurysm formation through inhibition of macrophage activation.
Discussion
MMP9 is known as a marker of classical macrophage activation and as contributing to aneurysm formation through the degradation of type IV collagen and matrix. [19] [20] [21] In the present study, we demonstrated that TNF-a plus CaPO 4 robustly increases Mmp9 mRNA expression and protein secretion compared with TNF-a alone in RAW264.7 cells. We previously reported that CaPO 4 contributes to aneurysm formation through the apoptosis of vascular smooth muscle cells with subsequent macrophage infiltration. 17 Consequently, the activation could be the result of enhanced apoptosis and an indirect positive effect of CaPO 4 on classical macrophage activation. Several studies have reported that there is a reduced risk of aneurysm in DM patients, 5, 11, 12 and it is likely that multiple mechanisms underlie this effect. Our current study showed the inhibitory effect of type 1 and 2 DM on murine aneurysm. We suggest that the inhibitory effect is, at least in part, caused by suppression of macrophage activation because an in vitro assay using TNF-a plus CaPO 4 also showed an inhibitory effect of hyperglycemia on macrophage activation. Hyperglycemia, however, shows no migratory activity in RAW264.7 cells ( Figure S1 ) and caspase-3 activity in the MOVAS mouse vascular smooth muscle cell line ( Figure S2 ). Consequently, hyperglycemia suppresses macrophage activation without affecting migratory activity in macrophages and apoptopic activity in vascular smooth muscle cells. To further investigate the underlying mechanisms by which hyperglycemia suppresses macrophage activation, we focused on the nuclear receptor Nr1h2, which was once categorized as an orphan receptor but later was found to act as a glucose sensor. 7 Interestingly, Nr1h2 expression was suppressed by stimulation with TNF-a plus CaPO 4 under normal glucose conditions but was not affected under high-glucose conditions. Furthermore, activation of Nr1h2 by the agonist GW3965 mimicked the high-glucose effect in macrophages and suppressed Mmp9 expression and secretion. In contrast, deactivation of this receptor by siRNA canceled the suppressive effect of high glucose on Mmp9 mRNA expression and protein secretion. Together with the results showing suppression of macrophage activation and aneurysm in type 1 and 2 diabetic mice and GW3965-treated mice, these results suggest that hyperglycemia suppresses macrophage activation and aneurysm through the activation of Nr1h2.
The remaining challenges include a lack of understanding of the underlying pathway through which Nr1h2 suppresses Mmp9 expression and classical macrophage activation, as mentioned earlier. A possible pathway could be through nuclear factor jB, which is thought to play a pivotal role in TNF-a-induced inflammatory signaling. Joseph et al reported that the activation of Nr1h (LXR) decreases inducible nitric oxide synthase and cyclooxygenase 2 expression by antagonizing nuclear factor jB signaling in murine peritoneal macrophages. 22 A previous study also showed that nuclear factor jB contributes to lipopolysaccharide-induced mouse Mmp9 expression in RAW264.7 cells. 23 Consequently, further research focusing on the relationship between high glucose-induced activation of Nr1h2 and the nuclear factor jB signaling pathway as well as subsequent macrophage activation is warranted. We used the carotid artery instead of the abdominal aorta for the mouse aneurysm model. Although another group has used the carotid artery as a model for aortic aneurysm, 24 possible physiological differences between these anatomical structures make the carotid artery an imperfect model and is a limitation of this study.
In conclusion, we showed that the inhibitory effect of DM on mouse aneurysm formation depends on suppression of macrophage activation in the arterial wall. An in vitro assay showed inhibitory effects of hyperglycemia on macrophage activation, possibly through Nr1h2 activation. Activation of Nr1h2 by GW3965 suppressed aneurysm formation in mice. Taken together, our results indicate the inhibitory effect of DM on aneurysm through the inhibition of macrophage activation by Nr1h2. Although further research is warranted to elucidate the underlying mechanisms, GW3965 could lead to a novel therapeutic approach to aneurysm.
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